To start the year, Noxopharm CEO Dr Gisela Mautner is featured in a great article from BioSpectrum Asia on why mRNA technology represents a huge opportunity for the APAC region. www.biospectrumasia.com/analysis/29/...

Noxopharm has announced the first multiple-dose cohort of SOF-SKN™ has been successfully completed in the HERACLES trial. The Safety Steering Committee determined the treatment to be safe and well tolerated, with no clinically relevant issues found. More here: www.noxopharm.com/pdf/239710c2...

Noxopharm has released its 2025 AGM presentation covering inflammation’s links to numerous diseases, HERACLES clinical trial progress, external interest, market opportunities and catalysts, and SOF-SKN™ advantages in a global market. Read more here: www.noxopharm.com/pdf/f67956fe...

Noxopharm has announced the first dosing has been administered in the second part of the HERACLES clinical trial. This second part of the trial involves multiple doses of SOF-SKN being given to two cohorts in succession. Read more here: www.noxopharm.com/pdf/ddeef22f...

Noxopharm announces the awarding of a TechVoucher grant for a joint project with UNSW Sydney, who will use the funding to explore how Noxopharm’s novel anti-inflammatory oligonucleotides could be used to reduce the inflammation caused by implants. Read more here: www.noxopharm.com/pdf/8263eb2b...

Lupus can have severe effects on people's lives and can be hard to diagnose - read more about the disease and the latest global research in the article below. apnews.com/article/auto...  Disease of 1,000 faces shows how science is tackling immunity’s dark side

Noxopharm announces the start of the HERACLES clinical trial Part II, following successful single-dose testing. Multiple doses of ascending concentrations of SOF-SKN will continue safety testing at a more intensive level over a longer period of time. More here: www.noxopharm.com/pdf/1126c863...

The latest quarterly is now out, with news that Noxopharm has signed several collaboration agreements with Australian and international academic and research institutions. Read more here: www.noxopharm.com/pdf/07c5e9d5...

Great to see the Victorian Government supporting @hudsonresearch.bsky.social and Noxopharm's work taking our innovative SOF-SKN drug to a clinical trial and offering hope to people with lupus. www.premier.vic.gov.au/world-first-...

Noxopharm has announced it has been granted its first US patent for the Sofra™ technology platform. It relates to how Noxopharm’s innovative immune-modulatory oligonucleotides could harness the immune system for the treatment of certain cancers. Read more here: www.noxopharm.com/pdf/96da7dc3...

The immune system is centre stage once again as this year's Nobel Prize in Physiology or Medicine is awarded for groundbreaking discoveries concerning peripheral immune tolerance. www.nobelprize.org/prizes/medic...

Check out the company's latest media coverage on Stockhead. Noxopharm has the 'burning fire' of inflammation squarely in its sights: stockhead.com.au/health/biocu...

Noxopharm announces the fourth and last single-dose cohort of SOF-SKN™, a novel drug candidate for autoimmune diseases, has been successfully completed in the HERACLES trial. Read more here: www.noxopharm.com/pdf/e50f60a8...

Noxopharm has released a new Sofra™ presentation that includes an overview of the technology platform, global autoimmune disease therapeutics and cutaneous lupus market info, SOF-SKN advantages, and numerous catalysts. Read it here: www.noxopharm.com/pdf/a11601fa...

Noxopharm announces the third dose cohort of SOF-SKN™, a novel drug candidate for autoimmune diseases, has been successfully completed in the HERACLES trial. The fourth cohort will now receive the highest dose approved for this trial. Read more here: www.noxopharm.com/pdf/42f7ce25...

Noxopharm is very proud to have been nominated as a finalist in this year's Health Industry Hub awards, which celebrate change-makers across the industry. Read more about all the categories and finalists here: www.healthindustryhub.com.au/health-indus...

Noxopharm announces the second dose cohort of SOF-SKN™, a novel drug candidate for autoimmune diseases, has been successfully completed in the HERACLES trial. It will now proceed to the third cohort of participants, who will receive a higher dose. Read more here: www.noxopharm.com/pdf/51866b0a...

Noxopharm has announced initial results from US company Tezcat Biosciences testing assets from the Sofra™ technology platform. Tezcat conducted a series of preclinical in vitro studies that resulted in highly promising outcomes. Read more here: www.noxopharm.com/pdf/6d742ee9...

Noxopharm has expanded the scope of its existing collaborations with three companies following the signing of Material Transfer Agreements several months previously. Read more news in the latest quarterly here: www.noxopharm.com/pdf/65a545cf...

Noxopharm CEO Dr Gisela Mautner has featured as a panelist at Bio Connections Australia this week. The panel of accomplished female leaders discussed the role of women in the industry and how biotech companies can attract and retain more women in executive and scientific roles.

Noxopharm announces the first dose cohort of SOF-SKN™, a novel drug candidate for autoimmune diseases, has been successfully completed in the HERACLES trial. It will now proceed to the second cohort of participants, who will receive a higher dose. Read more here: www.noxopharm.com/pdf/8dbd34b1...

A major milestone reached with the first dose administered in the HERACLES trial for SOF-SKN™, a novel drug candidate for autoimmune diseases. Noxopharm CEO Dr Gisela Mautner said: “We have taken our first Sofra drug candidate into the clinic at a rapid pace.” www.noxopharm.com/pdf/e997b104...

Noxopharm has announced that recruitment activities are progressing rapidly for the HERACLES clinical trial. This involves activities such as advertising, as well as the identification, pre-screening and full screening of participants. Read more here: www.noxopharm.com/pdf/818fbb39...

Noxopharm has announced positive data generated by an overseas company that has tested novel assets from the Sofra™ platform. BioRay Pharmaceutical is a pioneer in China’s biopharmaceutical industry focusing on immune-mediated diseases. Read more here: www.noxopharm.com/pdf/8b484f06...

Noxopharm has secured Human Research Ethics Committee approval for the HERACLES first-in-human clinical trial of SOF-SKN™, a novel drug candidate for inflammatory diseases. Work now begins on site initiation, logistics, and participant recruitment. Read more here: www.noxopharm.com/pdf/558ce5d0...

Noxopharm has presented clinically relevant SOF-SKN™ data at the Australian Rheumatology Association’s Annual Scientific Meeting, marking the company's first engagement at a specialist rheumatology event. Read more here: www.noxopharm.com/pdf/31e0094f...

Noxopharm has now applied for Human Research Ethics Committee approval for the HERACLES clinical trial. CEO Dr Gisela Mautner said: “The preclinical testing phase has gone extremely well, and we have advanced our program expeditiously.” Read more here: www.noxopharm.com/pdf/4adb03b0...

Noxopharm has signed a follow-on MTA with an international company to widen the scope of an ongoing project. CEO Dr Gisela Mautner said: “We continue to see external interest growing in our Sofra technology.” Read more in the latest quarterly here: www.noxopharm.com/pdf/11c1c8db...

Noxopharm CEO Dr Gisela Mautner said: “The accelerated pace with which we have progressed SOF-SKN reflects our determination to explore the potential of this innovative technology in a clinical setting as quickly as possible.”

Noxopharm’s SOF-SKN™ lupus medication has passed its final in vivo preclinical safety study ahead of regulatory submission for the upcoming HERACLES clinical trial. No clinically relevant safety issues were identified. Read more here: www.noxopharm.com/pdf/131265aa...

Noxopharm has announced an expanded program of work with Melbourne’s Hudson Institute, broadening research into critical inflammation sensors as well as their relevance to cancer. Read more here, including insight into the discovery underlying the Sofra platform: www.noxopharm.com/pdf/c595367b...

Noxopharm has engaged Doherty Clinical Trials, a highly-regarded Australian Phase 1 Unit, to deliver the upcoming HERACLES clinical trial in Melbourne. Read more here: www.noxopharm.com/pdf/7796f57f...

Great work is being done by the volunteers at www.dragonclaw.net, a patient and carers-led charity supporting people suffering from autoimmune inflammatory diseases. Here’s a new video of their lupus meeting series: drive.google.com/file/d/1k62U...

The Alliance for mRNA Medicines is doing great work supporting the industry, and Noxopharm is proud to be a member. Read their latest research report below, which offers real-world insights into the evolving mRNA landscape. assets.mrnamedicines.org/uploads/2025...